Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G C Morton

Showing results (1-10 of 12) with videos related to

Pageof 2
Sort By:
Current Problems in Cancer|April 5, 2000
Early prostate cancerG C Morton
Clinical Oncology (Royal College of Radiologists (Great Britain))|July 7, 2005
The emerging role of high-dose-rate brachytherapy for prostate cancerG C Morton
Clinical Oncology (Royal College of Radiologists (Great Britain))|December 4, 2019
High Dose Rate Brachytherapy in High-Risk Localised Disease - Why Do Anything Else?G C Morton, S M Alrashidi
Current Opinion in Obstetrics & Gynecology|February 1, 1996
Does adjuvant chemotherapy change the prognosis of cervical cancer?G C Morton, G M Thomas
Annals of the Academy of Medicine, Singapore|May 1, 1996
Is there a place for whole abdominal radiotherapy in the management of ovarian cancer?G C Morton, G M Thomas
Cancer Treatment and Research|June 10, 1998
Advances in the radiotherapy of gynecologic malignanciesG C Morton, G M Thomas
Clinical Oncology (Royal College of Radiologists (Great Britain))|June 4, 2013
Brachytherapy: current status and future strategies -- can high dose rate replace low dose rate and external beam radiotherapy?G C Morton, P J Hoskin
The Canadian Journal of Urology|December 16, 2000
Should pathological T3 and/or margin positive prostate cancer receive adjuvant therapy? A radiation oncologist's viewC R Choo, C Danjoux, G C Morton
Therapeutic Drug Monitoring|August 1, 1997
Pharmacokinetics of mercaptopurine: plasma drug and red cell metabolite concentrations after an oral doseJ Welch, L Lennard, G C Morton, et al.
American Journal of Therapeutics|September 22, 2006
Rise in prostate-specific antigen in men with untreated low-grade prostate cancer is slower during spring-summerR Vieth, R Choo, L Deboer, et al.
Pageof 2

Showing results (1-10 of 12) with videos related to

Sort By:
Pageof 2
Current Problems in Cancer|April 5, 2000
Early prostate cancerG C Morton
Clinical Oncology (Royal College of Radiologists (Great Britain))|July 7, 2005
The emerging role of high-dose-rate brachytherapy for prostate cancerG C Morton
Clinical Oncology (Royal College of Radiologists (Great Britain))|December 4, 2019
High Dose Rate Brachytherapy in High-Risk Localised Disease - Why Do Anything Else?G C Morton, S M Alrashidi
Current Opinion in Obstetrics & Gynecology|February 1, 1996
Does adjuvant chemotherapy change the prognosis of cervical cancer?G C Morton, G M Thomas
Annals of the Academy of Medicine, Singapore|May 1, 1996
Is there a place for whole abdominal radiotherapy in the management of ovarian cancer?G C Morton, G M Thomas
Cancer Treatment and Research|June 10, 1998
Advances in the radiotherapy of gynecologic malignanciesG C Morton, G M Thomas
Clinical Oncology (Royal College of Radiologists (Great Britain))|June 4, 2013
Brachytherapy: current status and future strategies -- can high dose rate replace low dose rate and external beam radiotherapy?G C Morton, P J Hoskin
The Canadian Journal of Urology|December 16, 2000
Should pathological T3 and/or margin positive prostate cancer receive adjuvant therapy? A radiation oncologist's viewC R Choo, C Danjoux, G C Morton
Therapeutic Drug Monitoring|August 1, 1997
Pharmacokinetics of mercaptopurine: plasma drug and red cell metabolite concentrations after an oral doseJ Welch, L Lennard, G C Morton, et al.
American Journal of Therapeutics|September 22, 2006
Rise in prostate-specific antigen in men with untreated low-grade prostate cancer is slower during spring-summerR Vieth, R Choo, L Deboer, et al.
Pageof 2